We can’t show the full text here under this license. Use the link below to read it at the source.
Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6)
Tirzepatide improved quality of life more than insulin lispro in adults with type 2 diabetes already using basal insulin and with poor blood sugar control
AI simplified
Abstract
Among 1428 participants with type 2 diabetes, those receiving tirzepatide showed statistically significant improvements in compared to those treated with insulin lispro at 52 weeks.
- Participants in the tirzepatide group had better scores in all domains of the Short Form-36 Health Survey version 2 compared to the insulin lispro group.
- The most notable improvements in health-related quality of life were observed in general health, vitality, and mental health domains.
- Tirzepatide-treated participants also experienced significant enhancements in daily living activities and self-perception related to weight.
- Higher scores were recorded in the EQ visual analogue scale and EQ-5D-5L index for those receiving tirzepatide after adjusting for baseline measurements.
- Overall, tirzepatide treatment is associated with improved health-related quality of life and glycaemic control compared to prandial insulin therapy.
AI simplified
Key numbers
p < 0.05
Improvement in
Comparison of SF-36v2 scores at 52 weeks between treatment groups.
67.5% of tirzepatide-pooled participants
target achievement
Proportion of participants meeting target of < 7.0% at 52 weeks.
−12.2 kg
Weight loss difference
Mean difference in weight change from baseline at 52 weeks.